An miR-502–Binding Site Single-Nucleotide Polymorphism in the 3′-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset
暂无分享,去创建一个
George A Calin | Wei Zhang | Fengju Song | Kexin Chen | Wei Zhang | G. Calin | F. Song | Sheng Wei | Q. Wei | Kexin Chen | X. Hao | H. Dai | Hong Zheng | Lina Zhang | Lina Zhang | Hong Zheng | Xishan Hao | Qingyi Wei | Sheng Wei | Ben Liu | Ben Liu | Hongji Dai | Kexin Chen
[1] Paul Tempst,et al. Regulation of p53 activity through lysine methylation , 2004, Nature.
[2] D. Malkin,et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. , 2007, Cancer research.
[3] G. Zhu,et al. SET8 plays a role in controlling G1/S transition by blocking lysine acetylation in histone through binding to H4 N-terminal tail , 2008, Cell cycle.
[4] A. Børresen-Dale,et al. TP53 mutations in synchronous and metachronous bilateral breast carcinomas. , 2008, Cancer genetics and cytogenetics.
[5] H. Meijers-Heijboer,et al. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family , 2007, Familial Cancer.
[6] C. Morrison,et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.
[7] G. Zhu,et al. SET8 Recognizes the Sequence RHRK20VLRDN within the N Terminus of Histone H4 and Mono-methylates Lysine 20* , 2005, Journal of Biological Chemistry.
[8] T. Crook,et al. The p53 pathway in breast cancer , 2002, Breast Cancer Research.
[9] C. Burge,et al. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.
[10] K. McManus,et al. Catalytic Function of the PR-Set7 Histone H4 Lysine 20 Monomethyltransferase Is Essential for Mitotic Entry and Genomic Stability* , 2008, Journal of Biological Chemistry.
[11] Michael Kertesz,et al. The role of site accessibility in microRNA target recognition , 2007, Nature Genetics.
[12] V. Scaria,et al. MicroRNA-mediated up-regulation of an alternatively polyadenylated variant of the mouse cytoplasmic β-actin gene , 2008, Nucleic acids research.
[13] S. Hussain,et al. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. , 2006, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[14] Jian-Fu Chen,et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.
[15] Alexei Vazquez,et al. The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.
[16] Hengbin Wang,et al. Purification and Functional Characterization of SET8, a Nucleosomal Histone H4-Lysine 20-Specific Methyltransferase , 2002, Current Biology.
[17] Shuomin Zhu,et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis , 2008, Cell Research.
[18] T. Dalmay,et al. The cartilage specific microRNA‐140 targets histone deacetylase 4 in mouse cells , 2006, FEBS letters.
[19] K. Hemminki,et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. , 2007, Carcinogenesis.
[20] K. Darvishi,et al. Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism , 2007, Breast Cancer Research.
[21] A. Mills,et al. p53: at the crossroad between cancer and ageing , 2007, The Journal of pathology.
[22] Wei Zhang,et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. , 2007, Carcinogenesis.
[23] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[24] M. Fraga,et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.
[25] F. Slack,et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. , 2008, Cancer research.
[26] Jian Gu,et al. Single Nucleotide Polymorphisms of microRNA Machinery Genes Modify the Risk of Renal Cell Carcinoma , 2008, Clinical Cancer Research.
[27] Or Gozani,et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. , 2007, Molecular cell.
[28] R. Catarino,et al. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. , 2005, Cancer genetics and cytogenetics.
[29] Z. Shao,et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. , 2008, Carcinogenesis.
[30] Robert Johansson,et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. , 2008, Carcinogenesis.
[31] Angélica Rangel-López,et al. Variaciones genéticas del gen supresor de tumores TP53: relevancia y estrategias de análisis , 2006 .
[32] Hongbing Shen,et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. , 2008, The Journal of clinical investigation.
[33] Gaofeng Wang,et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.
[34] Debashis Ghosh,et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[35] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[36] David J. Hunter,et al. The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies , 2006, Cancer Causes & Control.
[37] Joseph S Brunzelle,et al. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. , 2005, Genes & development.
[38] A. Levine,et al. Single-nucleotide polymorphisms in the p53 pathway. , 2005, Cold Spring Harbor symposia on quantitative biology.
[39] Guy Leclercq,et al. p53 and breast cancer, an update. , 2006, Endocrine-related cancer.
[40] Kristian Helin,et al. EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.
[41] Junjie Chen,et al. Direct Interaction between SET8 and Proliferating Cell Nuclear Antigen Couples H4-K20 Methylation with DNA Replication* , 2008, Journal of Biological Chemistry.
[42] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[43] Edwin Wang,et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers , 2007, Nucleic acids research.
[44] K. Helin,et al. The histone methyltransferase SET8 is required for S-phase progression , 2007, The Journal of cell biology.
[45] Yu-Ping Yang,et al. The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone , 2004, Breast Cancer Research.
[46] F. Tsai,et al. p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases , 2008, Journal of clinical laboratory analysis.
[47] Tom Walsh,et al. Ten genes for inherited breast cancer. , 2007, Cancer cell.
[48] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[49] Hua Zhao,et al. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. , 2008, Carcinogenesis.